Navigation Links
RoosterBio Partners with Senti Biosciences to Rapidly Translate Gene Circuit Cell Therapy into the Clinic
Date:3/19/2020

RoosterBio Inc. announces a clinical supply and manufacturing collaboration agreement with pioneering gene circuit company Senti Biosciences, Inc. (Senti) to accelerate the clinical translation of Senti’s gene-modified cell therapies for ovarian cancer and other solid tumor indications. The collaboration will leverage RoosterBio’s human mesenchymal stem/stromal cell (hMSC) bioprocess systems, rapid product and process development platform, and current Good Manufacturing Practices (cGMP)-compliant, hMSC-focused manufacturing capabilities.

“Gene-modified cell therapies are one of the most important segments in our industry, and we are excited to help Senti Biosciences accelerate its technology into the clinic,” said RoosterBio’s Founder & Chief Product Officer Jon A. Rowley, PhD. “Our collaboration reflects the importance of strategically positioned gene engineering platforms that are designed for rapid clinical translation. RoosterBio’s goal of radically simplifying hMSC product development, process development and clinical manufacturing are being leveraged to move the field of cell therapy forward.”

“Gene circuits have the potential to lead the next wave of cell and gene therapies to address the high unmet need in difficult-to-treat cancers, such as ovarian cancer” said Philip Lee, PhD, Senti’s Chief Operating Officer and Co-Founder. “We look forward to continuing our collaboration with RoosterBio to accelerate clinical development of our novel gene circuit MSC-based therapies to help bring those therapies to patients as efficiently and safely as possible.”

Under the terms of the agreement, Senti will apply its novel gene circuit technology to hMSCs produced by RoosterBio’s breakthrough CliniControl™ hMSC manufacturing platform. In addition, Senti will employ RoosterBio for external development of hMSC supply and expansion, including bioreactor scale-up and industrialized large-scale manufacturing unit operations.

RoosterBio’s proprietary, clinically relevant product portfolio was introduced in 2017 under the CliniControl brand name with the promise to radically simplify multiple steps in therapeutic development. CliniControl is the first hMSC product to be commercialized as off-the-shelf, cGMP-compliant working cell bank and bioprocess media systems.

Rowley added, “We’ve shown that our CliniControl products can uniquely deliver and continue to drive unparalleled efficiencies and economies of scale in clinical and commercial hMSC manufacturing, helping our customers accelerate the development of exciting new cell therapy products.”

About RoosterBio, Inc.

RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio's products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field. Visit http://www.roosterbio.com.

About Senti Biosciences

Senti Biosciences is a next-generation therapeutics company that is developing gene circuits and programming cells for tremendous therapeutic value. Senti’s mission is to outsmart complex diseases with more intelligent medicines that will transform people’s lives. By programming cells to respond, adapt and make decisions, Senti is creating smarter therapies with computer-like logic, enhanced functionality and greater therapeutic control.

Senti’s product candidates address major challenges in cancer treatment. To overcome cancer immune evasion, Senti is building cell therapies equipped with combinatorial arming gene circuits to elicit broad and sustained anti-tumor immune responses. Senti is also developing next-generation cell therapies that more precisely target and eliminate cancer cells while sparing healthy tissue.

Senti Biosciences is based in South San Francisco and was founded in 2016 by Drs. Tim Lu, Philip Lee, Jim Collins and Wilson Wong. Senti is proud to count NEA, 8VC, Amgen Ventures, Lux Capital, Menlo Ventures, Pear Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital among its investors.

Read the full story at https://www.prweb.com/releases/roosterbio_partners_with_senti_biosciences_to_rapidly_translate_gene_circuit_cell_therapy_into_the_clinic/prweb16984365.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. RoosterBio and GenCure Sign Multiple Agreements to Advance Regenerative Medicine Startups
2. RoosterBio Launches New cGMP Stem Cell Product Portfolio, Maintaining Unwavering Commitment to Driving the Explosive Regenerative Medicine Industry
3. Margot Connor, CEO, RoosterBio Inc., Frederick Innovative Technology Center, Inc expected graduate earns “Top 10” Technology Industry Award
4. RoosterBio Launches a Xeno-Free Bioreactor Feed to Streamline Cell Expansion & Efficiently Reach Billions of hMSCs
5. RoosterBio Inc. Unites with Manufacturing Innovation Institutes, Joining Manufacturing USA Network
6. Engineered by RoosterBio Inc.: Universal Bioprocess Bags to Streamline Closed System Stem Cell Production
7. Designed by RoosterBio Inc.: New Xeno-free Cell Culture Media Product Developed to Accelerate Manufacturing and Commercialization of Adult Stem Cell Products
8. RoosterBio Inc. Launches Industry’s First Ready-to-Print Stem Cell Product
9. Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology
10. Shoreline Biome Announces New Asian Distribution Partnership
11. With the Industry Booming, Slone Partners Celebrates 20 Years as a Leader in Life Sciences and Biotech Executive Search
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... ... now offering an Amniosomes special offer. This includes buy three, get the fourth ... call (888) 568-6909. , Amniotic derived exosomes, known as exosomes, have been a ...
(Date:6/19/2020)... Russia (PRWEB) , ... June 18, 2020 , ... The ... 2018. Its goal is to join forces to radically prolong life and find a ... postpone the aging period. This project was supported by various scientists from all over ...
(Date:6/11/2020)... ... June 09, 2020 , ... TRX Systems, developer of ... Solution, a highly accurate, contact tracing solution for identification of employees who ... a core disease control measure, is a key strategy for preventing further spread ...
(Date:6/2/2020)... (PRWEB) , ... June 01, 2020 , ... ... hand to companies and encourage positive change in the world, enterprise security solutions ... pandemic. , With more people working from home during self-quarantines and shelter-in-place orders, ...
Breaking Biology Technology:
(Date:5/26/2020)... ... May 26, 2020 , ... ... R&D, today announced that Gritstone Oncology, Inc., a clinical-stage biotechnology company developing ... engagers and TCR-based therapeutics, has implemented Genedata Biologics ® within their ...
(Date:5/21/2020)... ... 20, 2020 , ... Law Enforcement has always been a highly stressful career ... positions of these men and women put them constantly in harm’s way both from ... Officers have always had to face very high daily stress. Now, COVID-19 introduces another ...
(Date:5/14/2020)... ... May 14, 2020 , ... ... medical sales representatives, found the 2019 average medical sales rep total compensation increased ... shadowed by uncertainties amid the COVID-19 global crisis. , The MedReps 2020 Salary ...
Breaking Biology News(10 mins):